TSHA logo

TSHA Taysha Gene Therapies, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$3.72
-0.05 (-1.33%)

Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development …

Market Cap: $1.21Bwww.tayshagtx.com

Price

No data yet.

Social Signal Score

48
5d
—
30d
50
2 mentions
—
60d
43
3 mentions
—
90d
51
4 mentions
—
news: 4

Analyst Ratings

18 analysts
Buyconsensus
Strong Buy 0Buy 15Hold 3Sell 0Strong Sell 0
Avg price target$14+276.3%
Low $13Median $14High $15
Current Consensus

Revenue

$0.00
$0.00$1.83M$3.66M$5.49M
Dec 2019Sep 2026

Analyst Estimates

FY2025
$-0.36
$-0.37–$-0.34
6 analysts
FY2026
$-0.44
$-0.51–$-0.41
7 analysts
FY2027
$-0.45
$-0.56–$-0.35
7 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sean Nolan
Sector
Healthcare
Industry
Biotechnology
Employees
99
Beta
1.17
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
6.53
www.tayshagtx.com